PTC Therapeutics announced that it has withdrawn the resubmission of its New Drug Application for Translarna (ataluren), a therapy for nonsense‑mutation Duchenne muscular dystrophy (nmDMD), after the U.S. Food and Drug Administration determined the submitted data were unlikely to meet the agency’s threshold of substantial evidence of effectiveness.
The decision follows a long history of regulatory challenges for Translarna. The FDA previously rejected the drug in 2016 and 2017 and has repeatedly requested additional well‑controlled clinical trials. In Europe, Translarna received conditional approval in 2014 but faced renewal difficulties, ultimately leading to the withdrawal of its EU authorization. The current withdrawal effectively ends PTC’s U.S. pursuit of approval for the drug.
Translarna has been a cornerstone of PTC’s DMD franchise, which generated $381.8 million in 2025 revenue, of which $235.5 million came from Translarna. The franchise’s decline has been driven by regulatory setbacks and competitive pressures, and the loss of a potential U.S. approval is expected to further erode future revenue streams.
CEO Matthew B. Klein said, “FDA shared that based on its review to date, the data in the NDA submission are unlikely to meet the Agency’s threshold of substantial evidence of effectiveness to support approval of Translarna. We have therefore made the decision to withdraw the NDA submission.” He added that the company has “worked tirelessly for over two decades to develop a safe and effective therapy for boys and young men affected by nonsense mutation DMD in the U.S.” and expressed disappointment that FDA approval could not be achieved.
The withdrawal underscores PTC’s strategic pivot toward newer growth engines. Sephience, approved in Japan, the EU, and the U.S. for phenylketonuria (PKU), generated $112.1 million in 2025 revenue, while the Novartis‑backed PTC518, a candidate for Huntington’s disease, remains in early development. Management views these assets as the primary drivers of future growth, given the regulatory uncertainty surrounding the legacy DMD portfolio.
The event has prompted a reassessment of PTC’s revenue outlook. Analysts now expect the company to rely more heavily on Sephience and PTC518, and the loss of Translarna’s U.S. potential is likely to tighten the company’s earnings guidance for the coming fiscal year.
The market reaction has been muted in terms of trading activity, but investor sentiment reflects concern over the erosion of the DMD franchise and the company’s ability to sustain its legacy revenue base while scaling its new pipeline.
Overall, the withdrawal represents a significant regulatory setback for PTC, but it also signals a clear shift toward a more diversified portfolio that could mitigate long‑term risk.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.